Retigabine (ezogabine in the U.S.), which activates KCNQ2/2 potassium channels, is effective as an adjunctive treatment in partial-onset seizures, according to the results of the phase III RESTORE 1 trial (French et al. Neurology 2011; 76: 1555-1563).
Latest News
ADAPT trial update: NSAIDs in AD
December 14, 2011The Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) was launched a decade ago to determine if an NSAID (naproxen 220 mg BID or celecoxib 200 mg BID) could delay the onset of AD (ADAPT Research Group et al. Alzheimers Dement 2009; 5: 93-104; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC2866447/pdf/nihms185404.pdf). The trial was suspended in 2004 following the finding from the Adenoma Prevention with Celecoxib (APC) trial of an increased cardiovascular risk with celecoxib (Solomon et al. N Engl J Med 2005; 352: 1071-1080; free full text at www.nejm.org/doi/full/10.1056/NEJMoa050405).
Indeed, data from ADAPT subsequently suggested an increased cardiovascular and cerebrovascular risk with celecoxib and naproxen (ADAPT Research Group. PLoS Clin Trials 2006; 1: e33; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC1851724/pdf/pctr.0010033.pdf).
Emerging MS therapies: update on injectable drugs
November 30, 2011REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – Late-breaking sessions at ECTRIMS 2011 presented phase III data for two novel MS therapies administered by injection/infusion.
CONFIRM – Second phase III trial results for BG-12
November 30, 2011REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – Just days after ECTRIMS, top-line results from the second of two phase III trials of BG-12 were announced in a press release (www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1621631) and in a webcast to investors (www.biogenidec.com/investors.aspx?ID=5494).